Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

The study demonstrated that deferasirox (DFX), an oral iron chelator, effectively reduced liver fibrosis and hepatocarcinogenesis in a rat model, particularly when combined with sorafenib. This combination therapy significantly decreased preneoplastic lesions and adverse effects like hand-foot skin syndrome, commonly associated with sorafenib. The findings suggested that DFX could be a promising adjunct therapy to enhance the efficacy and reduce the side effects of sorafenib in treating hepatocellular carcinoma (HCC).